QELBREE (viloxazine hydrochloride)
200 mg/1 · Extended-Release Capsule
By Supernus Pharmaceuticals, Inc
- NDC
- 17772-133
- Route
- Oral
- Therapeutic class
- Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Norepinephrine Reuptake Inhibitor , Norepinephrine Uptake Inhibitors [MoA]
- Marketing category
- NDA
Package sizes
- 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-07)NDC 17772-133-07Available to order
- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-30)NDC 17772-133-30Available to order
- 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-60)NDC 17772-133-60Available to order
- 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-90)NDC 17772-133-90Available to order
- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-01)NDC 17772-133-01Available to order
Additional information
Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.
Request this medication
Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

